GSK Launches Tender Offer for Nuvalent at $124 per Share
GSK (GSK) announced that Harmony Row Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline, which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase all of the issued and outstanding shares of Class A common stock and Class B common stock of Nuvalent (NUVL), for $124.00 per share, net to the seller in cash, without interest, subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the offer to purchase, dated June 24. The offer is being made pursuant to a previously announced agreement and plan of merger, dated as of June 9, the company noted.
